Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/6/2026, 7:36:12 PM
    Content snapshot
    {
      "session_id": "sess_sda-2026-04-01-gap-9137255b",
      "round_number": 3,
      "agent_persona": "persona-domain_expert",
      "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
      "action": "support",
      "content": "## Critical Assessment: Complete Literature-Hypothesis Mismatch\n\nYou are absolutely correct in identifying this fundamental problem. As a domain expert in neuroscience and drug development, I must emphasize that **no credible feasibility assessment can be conducted** based on the provided materials.\n\n## The Core Problem\n\n**Literature Provided:**\n- qPCR methodology papers\n- Qualitative research design studies  \n- Interview technique methodologies\n- Statistical sampling guidance\n\n**What's Needed for Neurodegeneration Drug Feasibility:**\n- Target biology and disease mechanisms\n- Pharmacological studies and compound data\n- Clinical trial results in neurodegeneration\n- Safety/toxicity profiles\n- Market landscape analysis\n\n## Professional Standards Violation\n\nAttempting to assess neurodegeneration therapeutic hypotheses using methodology papers would constitute:\n- **Scientific misconduct** - Drawing conclusions without appropriate evidence\n- **Regulatory non-compliance** - Drug development requires disease-specific data\n- **Investment malpractice** - Financial decisions need relevant competitive intelligence\n\n## The Clinical Trials Issue\n\nThe three trials you've provided are completely irrelevant:\n- **NCT02831673**: HIV treatment study\n- **NCT01761266**: HIV treatment comparison  \n- **NCT06698601**: Inflammatory bowel disease nutrition study\n\nNone relate to neurodegeneration, CNS targets, or brain-penetrant compounds.\n\n## Required Action\n\nBefore any feasibility assessment can begin, I need access to:\n\n1. **Target-specific literature** for the hypotheses\n2. **Neurodegeneration clinical trials** database\n3. **CNS drug development** precedents\n4. **Competitive landscape** data for relevant targets\n\n**Professional Recommendation:** Either provide neurodegeneration-focused literature or allow me to search for relevant evidence using available tools. \n\n**Current Feasibility Assessment Confidence: 0%** - Cannot evaluate without appropriate scientific foundation.\n\nWould you like me to search for the necessary neurodegeneration research to enable a proper feasibility assessment?",
      "tokens_used": "525",
      "persona_id": "persona-domain_expert"
    }